These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26043724)

  • 1. Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes.
    Nordenmark LH; Taylor R; Jorup C
    Adv Ther; 2015 Jun; 32(6):548-66. PubMed ID: 26043724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
    Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
    COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
    Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
    Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
    Celli B; Halpin D; Hepburn R; Byrne N; Keating ET; Goldman M
    Respir Med; 2003 Jan; 97 Suppl A():S35-43. PubMed ID: 12564609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
    Laursen LC; Lindqvist A; Hepburn T; Lloyd J; Perrett J; Sanders N; Rocchiccioli K
    Respir Med; 2003 Jan; 97 Suppl A():S23-33. PubMed ID: 12564608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD.
    Gunawardena KA; Gullstrand H; Perrett J
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):288-304. PubMed ID: 23391369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of CT quantified emphysema, air trapping and airway wall thickness on pulmonary function in male smokers with and without COPD.
    Mohamed Hoesein FA; de Jong PA; Lammers JW; Mali WP; Mets OM; Schmidt M; de Koning HJ; Aalst Cv; Oudkerk M; Vliegenthart R; Ginneken Bv; van Rikxoort EM; Zanen P
    COPD; 2014 Sep; 11(5):503-9. PubMed ID: 25093696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
    Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of cilomilast in COPD.
    Rennard S; Knobil K; Rabe KF; Morris A; Schachter N; Locantore N; Canonica WG; Zhu Y; Barnhart F
    Drugs; 2008; 68 Suppl 2():3-57. PubMed ID: 19105585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
    Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
    Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.